Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Unlock the editor’s digestion free
FT editor Roula Khalaf, chooses his favorite stories in this weekly newsletter.
If investors warn Astrazeneca In New York list, London would be a loss for the entire market and the potential England economy.
A fund manager in Aberdeen Iain Pyle, the largest FTSE company left the UK market, he said. Astrazeneca’s CEO, Sir Pascal Soriot, in the opinion of two people who are familiar with this issue, expressed their frustration with the UK environment.
“This is the largest name in the market and as a successful and innovative pharmaceutical company, he said,” Halo ‘.
Shares in AstraZeneca increased by 2.9 percent after a report on Tuesday, Soriot’un said he had private discussions in connection with a US list of US. AstraZeneca refused to comment.
Some AstraRazeneca shareholders may hope that the US list can increase the company’s assessment, because previously pipelines will take the time to understand previous medications.
A US list will facilitate payments for their managers, including Soriot and Heir. “PASK was the highest salary General in FTSE in 2023, but again US managers are given more money,” said Pyle.
Asking In 2023, 16.9 mln After hitting the longest targets. The average payment for the CEO of FTSE 100 is $ 6.5 million, Compared to $ 16 million For these guided companies listed in S & P 500.
Astrazeneca’s movement can also be seen as a political victory for the Trump Office, which puts pressure on the pharmaceutical industry Tariff threats and decrease in price.
In the UK, potential movement news, the United Kingdom is a concern among investors on the description of the attractions of the capital market and the effects of the sector of the financial services sector.
“If you are not in the background of a working capital market, it is an alarm,” said Sonja Laud, the main investor, which stresses the importance of the UK economy in London. “The tscal has damaged changes to improve liquidity and other measures to prevent the structure and other measures to prevent the structure.”
The UK market has suffered from a constant flow of companies that leads special lists or initial lists to the United States. Wise, which is listed in 2021, is the wise for the fintek, last month he said planned to change the main list From London to New York, referring to the deeper liquidity of the US market.
The threat of passing to the United States may have an awakening call to the British government, which is stuck in negotiations with the pharmaceutical industry. If companies do not spend more in the country, investing in England is at risk.
The government did not make any concrete decisions or set a specific decision on the list and a change in the list.
Soriot complained that the medications of the medication of AstraZeneca’s breast cancer medicine is valuable for the use of the NHS. Astrazeneca has invested in a factory in a factory in SPECEs in Speech, after the government has cut off their subsidies for the site.
Astrazeneca’nın ball 20 shareholders, the sector said the “tense period” with the British government. He said the government responded to this “threat types” as before moving to protect the automotive industry.
“In terms of the British economy, the loss of this list and accommodation, the UK science, production and research and development, development and development will risk the UK, which loses high valuables,” he said.
